RUNX1 and acute myeloid leukemia: Thus, AML1-ETO 3′UTR is an appropriate target for t(8;21) AML therapies due to importance of AML1-ETO expression to t(8;21) AML and the lack of wild type ETO expression in healthy hematopoietic cells.